Latest Insider Transactions at Lexicon Pharmaceuticals, Inc. (LXRX)
This section provides a real-time view of insider transactions for Lexicon Pharmaceuticals, Inc. (LXRX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of LEXICON PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of LEXICON PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 10
2024
|
Artal International S.C.A. |
BUY
Exercise of conversion of derivative security
|
Indirect |
57,546,100
+29.7%
|
-
|
|
Apr 28
2024
|
Christopher J Sobecki Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,032
+4.59%
|
-
|
|
Apr 28
2024
|
Judith L Swain Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,032
+14.24%
|
-
|
|
Apr 28
2024
|
Philippe Amouyal Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,032
+3.13%
|
-
|
|
Apr 28
2024
|
Sam L Barker Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,032
+8.39%
|
-
|
|
Apr 28
2024
|
Raymond Debbane Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,032
+0.59%
|
-
|
|
Apr 28
2024
|
Robert J Md Lefkowitz Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,032
+14.24%
|
-
|
|
Mar 13
2024
|
Artal International S.C.A. |
BUY
Grant, award, or other acquisition
|
Indirect |
1,150,922
+50.0%
|
$124,299,576
$108.5 P/Share
|
|
Feb 28
2024
|
Wendy Mc Dermott VP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
22,425
-29.85%
|
$44,850
$2.62 P/Share
|
|
Feb 28
2024
|
Wendy Mc Dermott VP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
46,641
+27.74%
|
-
|
|
Feb 28
2024
|
Jeffrey L Wade President and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
37,691
-10.41%
|
$75,382
$2.62 P/Share
|
|
Feb 28
2024
|
Jeffrey L Wade President and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
97,564
+8.83%
|
-
|
|
Feb 28
2024
|
Kristen Alexander VP, Finance and Accounting |
SELL
Payment of exercise price or tax liability
|
Direct |
11,793
-19.79%
|
$23,586
$2.62 P/Share
|
|
Feb 28
2024
|
Kristen Alexander VP, Finance and Accounting |
BUY
Exercise of conversion of derivative security
|
Direct |
29,243
+16.07%
|
-
|
|
Feb 28
2024
|
Brian T Crum SVP, General Counsel & Secr. |
SELL
Payment of exercise price or tax liability
|
Direct |
25,604
-12.61%
|
$51,208
$2.62 P/Share
|
|
Feb 28
2024
|
Brian T Crum SVP, General Counsel & Secr. |
BUY
Exercise of conversion of derivative security
|
Direct |
68,303
+11.07%
|
-
|
|
Feb 28
2024
|
Alan J Main EVP, Innov & Chem Sciences |
SELL
Payment of exercise price or tax liability
|
Direct |
24,408
-8.71%
|
$48,816
$2.62 P/Share
|
|
Feb 28
2024
|
Alan J Main EVP, Innov & Chem Sciences |
BUY
Exercise of conversion of derivative security
|
Direct |
67,546
+7.94%
|
-
|
|
Feb 28
2024
|
Lonnel Coats Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
61,371
-5.29%
|
$122,742
$2.62 P/Share
|
|
Feb 28
2024
|
Lonnel Coats Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
245,080
+6.96%
|
-
|
|
Feb 28
2024
|
Craig B Granowitz SVP, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
31,265
-39.63%
|
$62,530
$2.62 P/Share
|
|
Feb 28
2024
|
Craig B Granowitz SVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
63,706
+35.26%
|
-
|
|
Feb 28
2024
|
Kenneth B. Kassler Taub SVP, Regulatory & QA |
SELL
Payment of exercise price or tax liability
|
Direct |
24,353
-13.02%
|
$48,706
$2.62 P/Share
|
|
Feb 28
2024
|
Kenneth B. Kassler Taub SVP, Regulatory & QA |
BUY
Exercise of conversion of derivative security
|
Direct |
67,400
+11.79%
|
-
|
|
Nov 16
2023
|
Lonnel Coats Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
90,000
+8.96%
|
$90,000
$1.05 P/Share
|
|
Nov 10
2023
|
Lonnel Coats Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+1.2%
|
$10,000
$1.01 P/Share
|
|
Oct 12
2023
|
Raymond Debbane Director |
BUY
Open market or private purchase
|
Direct |
148,820
+9.99%
|
$148,820
$1.03 P/Share
|
|
Oct 11
2023
|
Raymond Debbane Director |
BUY
Open market or private purchase
|
Direct |
342,874
+22.34%
|
$342,874
$1.08 P/Share
|
|
Oct 10
2023
|
Raymond Debbane Director |
BUY
Open market or private purchase
|
Direct |
508,306
+37.45%
|
$508,306
$1.14 P/Share
|
|
Sep 14
2023
|
Jeffrey L Wade President and COO |
BUY
Open market or private purchase
|
Direct |
10,000
+3.65%
|
$10,000
$1.38 P/Share
|
|
Aug 04
2023
|
Wendy Mc Dermott VP, Human Resources |
BUY
Open market or private purchase
|
Direct |
6,000
+17.4%
|
$6,000
$1.84 P/Share
|
|
Jun 29
2023
|
Lonnel Coats Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+1.21%
|
$20,000
$2.16 P/Share
|
|
Jun 26
2023
|
Lonnel Coats Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+1.23%
|
$20,000
$2.18 P/Share
|
|
Jun 23
2023
|
Wendy Mc Dermott VP, Human Resources |
BUY
Open market or private purchase
|
Direct |
10,000
+30.79%
|
$20,000
$2.43 P/Share
|
|
Jun 23
2023
|
Lonnel Coats Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+1.24%
|
$20,000
$2.5 P/Share
|
|
Jun 22
2023
|
Lonnel Coats Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
40,000
+4.85%
|
$80,000
$2.31 P/Share
|
|
Jun 20
2023
|
Jeffrey L Wade President and COO |
BUY
Open market or private purchase
|
Direct |
12,000
+2.3%
|
$24,000
$2.34 P/Share
|
|
Jun 05
2023
|
Artal International S.C.A. |
BUY
Open market or private purchase
|
Indirect |
27,775,050
+26.1%
|
$55,550,100
$2.6 P/Share
|
|
May 21
2023
|
Alan S Nies Director |
BUY
Exercise of conversion of derivative security
|
Direct |
9,302
+18.48%
|
-
|
|
May 21
2023
|
Frank Palantoni Director |
BUY
Exercise of conversion of derivative security
|
Direct |
9,302
+18.74%
|
-
|
|
May 21
2023
|
Christopher J Sobecki Director |
BUY
Exercise of conversion of derivative security
|
Direct |
9,302
+5.53%
|
-
|
|
May 21
2023
|
Judith L Swain Director |
BUY
Exercise of conversion of derivative security
|
Direct |
9,302
+18.74%
|
-
|
|
May 21
2023
|
Philippe Amouyal Director |
BUY
Exercise of conversion of derivative security
|
Direct |
9,302
+18.74%
|
-
|
|
May 21
2023
|
Sam L Barker Director |
BUY
Exercise of conversion of derivative security
|
Direct |
9,302
+10.46%
|
-
|
|
May 21
2023
|
Raymond Debbane Director |
BUY
Exercise of conversion of derivative security
|
Direct |
9,302
+2.66%
|
-
|
|
May 21
2023
|
Robert J Md Lefkowitz Director |
BUY
Exercise of conversion of derivative security
|
Direct |
9,302
+18.74%
|
-
|
|
Feb 28
2023
|
Wendy Mc Dermott VP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
6,465
-34.13%
|
$12,930
$2.17 P/Share
|
|
Feb 28
2023
|
Wendy Mc Dermott VP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
18,943
+50.0%
|
-
|
|
Feb 28
2023
|
Kiernan Seth VP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,813
-18.19%
|
$23,626
$2.17 P/Share
|
|
Feb 28
2023
|
Kiernan Seth VP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
43,082
+22.03%
|
-
|